9515Background: PD-1/L1 inhibitors have transformed MM treatment, however many patients (pts) remain refractory. Subsequent treatment options including ipi offer modest benefit (~13% respond) (Long... Click to show full abstract
9515Background: PD-1/L1 inhibitors have transformed MM treatment, however many patients (pts) remain refractory. Subsequent treatment options including ipi offer modest benefit (~13% respond) (Long...
               
Click one of the above tabs to view related content.